A Food and Drug Administration advisory committee met Wednesday to examine whether an experimental cell therapy should be approved for heart damage associated with Duchenne muscular dystrophy, a progressive genetic disease that primarily affects boys and young men.

The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee is reviewing deramiocel, developed by Capricor Therapeutics, after agency scientists raised concerns about whether the clinical evidence proves that the treatment works.

No therapy is currently approved specifically to treat cardiomyopathy caused by Duchenne muscular dystrophy, according to FDA review materials.

That leaves families managing a disease that gradually weakens skeletal muscles while also damaging the heart. As patients live longer because of improvements in respiratory and supportive care, heart complications have become an increasingly important cause of illness and death.

Deramiocel is made from donor-derived heart cells and administered through an intravenous infusion. The treatment is intended to reduce inflammation and slow deterioration rather than replace damaged heart tissue.

Capricor is seeking approval based on clinical studies involving boys and young men with Duchenne muscular dystrophy.

Company officials say the results show that patients receiving deramiocel experienced slower declines in arm function and measures of cardiac performance compared with those receiving a placebo.

FDA reviewers questioned parts of that analysis before Wednesday’s meeting.

Agency documents said Capricor changed how certain trial results were calculated after the study was completed, including the methods used to assess upper-limb and heart function. Reviewers said those changes complicated their ability to determine whether the reported benefits were reliable.

Capricor has defended its approach, saying the final analysis plan was established before treatment assignments were revealed and that the broader evidence supports approval.

The disagreement places families between urgent medical need and uncertainty over the evidence.

Duchenne muscular dystrophy is caused by changes in the gene responsible for producing dystrophin, a protein that helps protect muscle fibers. Without enough functional dystrophin, muscles progressively weaken.

Symptoms often begin during early childhood. Many patients eventually lose the ability to walk and require assistance with breathing, mobility and daily activities.

Heart muscle can weaken even when a patient does not initially show obvious cardiac symptoms. That makes treatments capable of slowing heart deterioration especially important to families and physicians.

FDA advisory committees do not make final approval decisions. Their members review evidence, question company and agency scientists and issue recommendations that the FDA may consider before acting on an application.

The agency can approve a treatment, reject it or request additional studies and manufacturing information.

A favorable recommendation would not guarantee that deramiocel reaches patients. A negative recommendation would not automatically prevent approval, although the FDA usually gives significant weight to the conclusions of its outside experts.

Access and affordability would become the next major questions if the treatment is cleared.

Cell therapies are generally more complicated to manufacture, transport and administer than traditional pills. Patients may need specialized treatment centers, medical monitoring and repeat infusions.

Insurance coverage could therefore determine whether a federally approved therapy becomes practically available to families.

Capricor has proposed administering deramiocel once every three months. A recurring treatment schedule could create substantial long-term costs for insurers, government health programs and households if coverage is limited.

Those financial questions remain secondary until the FDA determines whether the therapy is effective and whether its benefits outweigh its risks.

Safety data reviewed by the agency included infusion-related reactions and other treatment-emergent complications. FDA staff did not identify the same type of severe liver injuries that have complicated some gene therapies for Duchenne, but reviewers continued examining whether the overall evidence supports repeated use.

Deramiocel differs from gene replacement treatments. It does not attempt to correct the genetic cause of Duchenne or instruct the body to produce a replacement form of dystrophin.

Instead, the therapy is designed to influence inflammation, scar formation and the body’s repair response. That could allow it to be used alongside other Duchenne treatments rather than replacing them.

Families and patient advocates participated in Wednesday’s public hearing, describing the daily consequences of progressive muscle and heart weakness and the limited options available once cardiac damage advances.

Their testimony highlights a recurring FDA challenge in rare diseases: patients may be willing to accept greater uncertainty because the condition is severe, while regulators must still require enough evidence to determine that a treatment provides real benefit.

Approving an ineffective therapy can expose patients to medical risk and financial cost while making future clinical trials harder to conduct. Requiring additional studies can delay access for people whose disease continues progressing while evidence is gathered.

Wednesday’s meeting is intended to help the FDA weigh those competing risks.

The agency has not yet made a final approval decision. Until the committee completes its review and the FDA acts, families should not interpret the hearing as confirmation that deramiocel is safe, effective or available for treatment.

What happens next will depend on the panel’s recommendation, the FDA’s assessment of the disputed trial analysis and whether regulators believe remaining questions can be resolved after approval—or require another controlled study first.

JBizNews Desk | Washington

© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.